Health> Vol.9 No.11, October 2017

University of Peloponnese, Corinth, Greece
University of Peloponnese, Corinth, Greece
Aristotle University of Thessaloniki, Thessaloniki, Greece
National and Kapodistrian University of Athens, Athens, Greece
Aristotle University of Thessaloniki, Thessaloniki, Greece
University of Ioannina, Ioannina, Greece
University of Patras, Patra, Greece
National and Kapodistrian University of Athens, Athens, Greece
National and Kapodistrian University of Athens, Athens, Greece
Janssen-Cilag Pharmaceutical SACI, Athens, Greece
Janssen-Cilag Pharmaceutical SACI, Athens, Greece
National and Kapodistrian University of Athens, Athens, Greece

 

Copyright © 2017 Mary Geitona, Hara Kousoulakou, Ioannis Goulis, Spilios Manolakopoulos, Themistoclis Vasiliadis, Dimitrios Christodoulou, Charalabos Gogos, Spyridon Dourakis, Ioannis George Koskinas, Alexandra Papadokostopoulou, Aris Lathouris, George Papatheodoridis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

 

How to Cite this Article

---

Geitona, M. , Kousoulakou, H. , Goulis, I. , Manolakopoulos, S. , Vasiliadis, T. , Christodoulou, D. , Gogos, C. , Dourakis, S. , George Koskinas, I. , Papadokostopoulou, A. , Lathouris, A. and Papatheodoridis, G. (2017) Managing Hepatitis C Patients in Greece: A Budget Impact Analysis of Simeprevir plus Pegylated Interferon/Ribavirin Regimen at Early Stages of the Disease. Health, 9, 1482-1493. doi: 10.4236/health.2017.911109.

 

Download citation as EndNote